Scarica l'app Stockscreener
6.59
3.37%
-0.23
Dopo l'orario di chiusura:
6.58
-0.010
-0.15%
Precedente Chiudi:
$6.82
Aprire:
$7.05
Volume 24 ore:
130.45K
Relative Volume:
2.67
Capitalizzazione di mercato:
$63.08M
Reddito:
$5.12M
Utile/perdita netta:
$-67.00M
Rapporto P/E:
-4.483
EPS:
-1.47
Flusso di cassa netto:
$-38.94M
1 W Prestazione:
+7.77%
1M Prestazione:
-18.30%
6M Prestazione:
+1.09%
1 anno Prestazione:
-87.50%
Intervallo 1D:
$5.93
$7.40
Intervallo di 1 settimana:
$5.93
$7.40
Portata 52W:
$3.816
$54.10
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Nome
Verrica Pharmaceuticals Inc
Settore
Industria
Telefono
484-453-3300
Indirizzo
10 NORTH HIGH STREET, WEST CHESTER, PA
Confronta VRCA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.59 | 63.08M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2023-03-22 | Iniziato | Jefferies | Buy |
| 2023-02-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-24 | Iniziato | Northland Capital | Outperform |
| 2020-03-24 | Iniziato | Needham | Buy |
| 2019-02-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica Pharmaceuticals stock price target raised to $20 by TD Cowen - Investing.com Canada
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript - Insider Monkey
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Sees Revenue Surge in Q2 2025 - TipRanks
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewswire
Verrica Posts Profit in Fiscal Q2 - The Motley Fool
Verrica Posts Profit in Fiscal Q2 - Nasdaq
Verrica Pharmaceuticals' Q2 2025: Unpacking Contradictions in Sales Strategies, Seasonality, and Patient Access - AInvest
Verrica Pharmaceuticals (VRCA) Q2 2025 Earnings and Strategic Pipeline Catalysts: A Case for Re-Rating and Investor Re-Entry - AInvest
Earnings call transcript: Verrica Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
VERRICA PHARMACEUTICAL Earnings Results: $VRCA Reports Quarterly Earnings - Quiver Quantitative
Verrica Pharmaceuticals earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Verrica VRCA 2025Q2 Earnings Preview Upside Potential on Strategic Expansion Plans - AInvest
Verrica Pharmaceuticals to Report Q2 Results on August 12 - MSN
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial - GuruFocus
Verrica Pharmaceuticals to Report Q2 2025 Financial Results and Provide Corporate Update on Aug 12, 2025. - AInvest
Verrica Pharmaceuticals to host Q2 earnings call on August 12, 2025. - AInvest
Verrica Pharmaceuticals: A Strategic Leap from Niche to Diversified Biotech Leader - AInvest
Verrica Pharmaceuticals to report second quarter 2025 financial results and provide a corporate update on August 12, 2025 - MarketScreener
Verrica Pharmaceuticals (VRCA): A Turning Point in 2025 Q2 Earnings and Strategic Momentum - AInvest
Verrica Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline - Stock Titan
Common Warts Clinical Trials, Companies, Therapeutic - openPR.com
Common Warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Ph - Barchart.com
Verrica Pharmaceuticals Inc. Consolidation Zone May Signal AccumulationTrade Setups With Clear Risk Limits Highlighted - metal.it
Published on: 2025-08-04 09:22:19 - metal.it
What drives Verrica Pharmaceuticals Inc. stock priceAchieve rapid capital gains with smart investing - Jammu Links News
What makes Verrica Pharmaceuticals Inc. stock price move sharplyGet alerts on the hottest stocks daily - Jammu Links News
What analysts say about Verrica Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - Jammu Links News
How volatile is Verrica Pharmaceuticals Inc. stock compared to the marketUnmatched profit potential - Jammu Links News
Is it the right time to buy Verrica Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
Should I hold or sell Verrica Pharmaceuticals Inc. stock in 2025Unlock market-leading stock analysis - Jammu Links News
Why is Verrica Pharmaceuticals Inc. stock attracting strong analyst attentionOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Verrica Pharmaceuticals Inc. stockOutperformance with explosive growth - Jammu Links News
What are the technical indicators suggesting about Verrica Pharmaceuticals Inc.Free Investment Community - Jammu Links News
How does Verrica Pharmaceuticals Inc. compare to its industry peersCapitalize on fast-moving trading opportunities - Jammu Links News
How many analysts rate Verrica Pharmaceuticals Inc. as a “Buy”Beginner Investor Insights That Work - jammulinksnews.com
What does recent volatility data suggest for Verrica Pharmaceuticals Inc.Minimal Risk Growth Investment Opportunity Analysis - Newser
Verrica Pharmaceuticals Implements Reverse Stock Split to Meet Nasdaq Requirements - AInvest
Leading vs lagging indicators on Verrica Pharmaceuticals Inc. performanceFree Multi-Bagger Potential Stock Forecast Tools - Newser
Market reaction to Verrica Pharmaceuticals Inc.’s recent newsSafe Investment Ideas with Growth Upside - Newser
Can machine learning forecast Verrica Pharmaceuticals Inc. recoveryAlgorithmic Prediction of Market Breakouts - Newser
Verrica Pharmaceuticals Implements Reverse Stock Split - TipRanks
Real time social sentiment graph for Verrica Pharmaceuticals Inc.Swing Setup With Technical Confirmation Explained - metal.it
Is Verrica Pharmaceuticals Inc. forming a bottoming baseTechnical Trade Plan with Entry Checklist - Newser
Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):